神经外科医师大会系统综述与循证指南:先进影像在成人新诊断WHO II级弥漫性胶质瘤中的作用(更新版)
本指南针对成人疑似或组织学证实的WHO II级弥漫性胶质瘤,评价先进MRI技术(磁共振波谱、灌注加权成像、扩散加权成像)及氨基酸PET示踪剂(FET、FDOPA)在肿瘤分级、边界、进展、治疗相关效应和预后评估中的作用,并给出以II级和III级证据为主的推荐意见。
要点
- 当T2加权及钆增强前后T1加权成像无法区分WHO II级与高级别胶质瘤时,建议(II级证据)使用扩散成像及DSC、DCE、ASL序列。
- 当扩散和灌注信息对临床有价值且无法通过其他方法获得时,建议(III级证据)用于基因组学、预后及治疗后监测。
- 当标准MRI、灌注和扩散技术无法区分时,建议(III级证据)使用MR波谱辅助鉴别WHO II级与高级别胶质瘤。
核心结论
- 对于成人疑似或组织学证实的WHO II级弥漫性胶质瘤,当常规MRI无法明确分级时,建议(II级或III级证据)使用扩散、灌注或MR波谱等先进MRI技术辅助鉴别。
- 氨基酸PET(FET、FDOPA)在MRI未能明确病变级别时建议(III级证据)用于鉴别低级别与高级别胶质瘤,并可在特定情况下辅助预后判断或检测肿瘤进展。
研究设计与样本
- 本指南由神经外科医师大会(Congress of Neurological Surgeons)制定,采用系统综述与循证方法,针对成人疑似或组织学证实的WHO II级弥漫性胶质瘤的影像学评估提出推荐。
主要发现
- 当T2加权及钆增强前后T1加权成像无法区分WHO II级弥漫性胶质瘤与高级别胶质瘤时,建议(II级证据)使用扩散成像及DSC、DCE、ASL序列。
- 当扩散和灌注信息对临床有价值且无法通过其他方法获得时,建议(III级证据)用于获取基因组学、预后及治疗后监测信息。
- 当标准MRI、灌注和扩散技术无法区分时,建议(III级证据)使用MR波谱辅助鉴别WHO II级与高级别胶质瘤。
- 若MRI未能明确病变级别,建议(III级证据)加用FET或FDOPA氨基酸PET辅助鉴别低级别与高级别胶质瘤。
- 当标准临床预后参数不明确且新型PET示踪剂可用时,临床医生可考虑(III级证据)使用FET辅助判断II级弥漫性胶质瘤患者的预后;若需额外信息检测肿瘤进展,临床医生可使用(III级证据)FDOPA PET联合MRI。
关键数值与推荐
- 推荐级别II:当T2加权及钆增强前后T1加权成像无法区分时,建议使用扩散成像及DSC、DCE、ASL序列鉴别WHO II级弥漫性胶质瘤与高级别胶质瘤。
- 推荐级别III:当信息对临床有价值且无法通过其他方法获得时,建议使用扩散和灌注成像获取基因组学、预后及治疗后监测信息。
- 推荐级别III:当标准MRI、灌注和扩散技术无法区分时,建议使用MR波谱鉴别WHO II级与高级别胶质瘤。
- 推荐级别III:若MRI未能明确,建议加用FET或FDOPA氨基酸PET辅助鉴别低级别与高级别胶质瘤。
- 推荐级别III:临床医生可考虑使用FET辅助预后判断,或使用FDOPA PET联合MRI检测肿瘤进展。
临床怎么用
- 对于成人疑似或组织学证实的WHO II级弥漫性胶质瘤,当常规MRI(T2加权及钆增强前后T1加权)无法明确分级时,可按指南建议(II级证据)加用扩散成像及DSC、DCE、ASL灌注序列。
- 若扩散和灌注信息对临床决策有价值且无法通过其他方法获得,可按指南建议(III级证据)用于基因组学、预后评估及治疗后监测。
- 当标准MRI、灌注和扩散技术仍无法区分时,可按指南建议(III级证据)使用MR波谱辅助鉴别。
- 若MRI未能明确病变级别,可按指南建议(III级证据)加用FET或FDOPA氨基酸PET;当标准预后参数不明确时,临床医生可考虑(III级证据)使用FET辅助预后判断,或使用FDOPA PET联合MRI检测进展。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TARGET POPULATION: Adult patients with suspected or histologically proven WHO Grade II diffuse glioma. QUESTION 1: In adult patients with suspected or histologically proven WHO Grade II diffuse glioma, do advanced MRI techniques using magnetic resonance spectroscopy, perfusion weighted imaging or diffusion weighted imaging provide superior assessment of tumor grade, margins, progression, treatment-related effects, and prognosis compared to standard neuroimaging? RECOMMENDATION: Level II: The use of diffusion imaging and dynamic susceptibility contrast (DSC), dynamic contrast enhancement (DCE) and arterial spin labeling (ASL) sequences are suggested to differentiate WHO Grade II diffuse glioma from higher grade gliomas when this is not accomplished by T2 weighted and pre- and post-gadolinium contrast enhanced T1 weighted imaging. LEVEL III: The use of diffusion and perfusion is suggested for obtaining information in genomics, prognosis, and post treatment monitoring when this information would be of value to the clinician and is not obtained through other methods. LEVEL III: The use of MR Spectroscopy is suggested to differentiate WHO Grade II diffuse glioma from higher grade gliomas when this is not accomplished by standard MRI, perfusion and diffusion techniques and when such information would be of value to the clinician. QUESTION 2: In adult patients with suspected or histologically proven WHO Grade II diffuse glioma, does molecular imaging using amino acid PET tracers provide superior assessment of tumor grade, margins, progression, treatment-related effects, and prognosis compared to standard neuroimaging? RECOMMENDATION: Level III: If not already evident by MRI studies, the addition of amino acid PET with FET and FDOPA as a tracer is suggested to help determine if a brain lesion is a low grade glioma or high grade glioma. LEVEL III: If the standard clinical prognostic parameters are unclear and novel PET tracers are available, the clinician may consider FET to assist in determination of prognosis in an individual with grade II diffuse glioma. LEVEL III: Clinicians may use FDOPA PET in addition to MRI if additional information is required for detection of tumor progression.
引用
- Badve C, Nirappel A, Lo S, et al. Congress of neurological surgeons systematic review and evidence-based guidelines for the role of imaging in newly diagnosed WHO grade II diffuse glioma in adults: update. J Neurooncol. 2025. PMID: 40338482. doi:10.1007/s11060-025-05043-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。